clinical trial · NCT07438444
A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity
Eli Lilly and Company·phase4·recruiting·n = 344
Diabetes Mellitus, Type 2ObesityOverweightTirzepatide
brief summary
The main purpose of this study is to measure the safety and efficacy of tirzepatide in adult participants in India who have type 2 diabetes or who have obesity or overweight without type 2 diabetes. Participation in the study will last about 46 weeks.
started
Feb 27, 2026
primary completion
Oct 1, 2027
completion
Oct 1, 2027
last updated
May 12, 2026
official title
A Phase 4, Open-Label, Single-Arm, 46-Week Study to Investigate the Safety and Efficacy With Tirzepatide in Adult Indian Participants With Either Type 2 Diabetes or Obesity
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol